GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.

GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)

GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals

Moderna

GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.

GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines

GSK PLC (LSE:GSK, NYSE:GSK) has shared promising results from two major clinical trials (ANCHOR-1 and ANCHOR-2) testing its new treatment, depemokimab, for people suffering from chronic rhinosinusitis with nasal polyps (CRSwNP). This condition causes painful inflammation and growths in the nasal passages, leading to breathing difficulties and other uncomfortable symptoms.

GSK hails phase III nasal polyps success

New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.

GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy

GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 2024 results, with a GBP 1.8 billion charge expected to impact the earnings per share by GBP 0.44. Despite the significant charge, GSK's forward non-GAAP P/E remains reasonable at 12.4x compared to peers and the 2025 figure looks even better.

GSK: The Worst Is Finally Over (Rating Upgrade)

GSK PLC (LSE:GSK, NYSE:GSK) US$2.2 billion settlement for 93% of Zantac litigation cases is almost a best-case scenario short of no payment, according to US broker Jefferies. The broker had pencilled liability costs of between US$2-3.5 billion for the liability, adding the deal is at the bottom of its expectations.

GSK Zantac settlement a 'clear win', say brokers

GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer.

GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement

GSK (GSK) shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes cancer.

GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US related to its discontinued heartburn medication, Zantac. The lawsuits alleged that the drug, which was pulled from the market, caused cancer.

GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn remedy causes cancer

GSK settles vast majority of Zantac claims for $2.2 billion

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $2.2 billion to settle around 80,000 US lawsuits concerning its heartburn medication Zantac, generically known as ranitidine. The plaintiffs alleged the drug caused cancer, although GSK maintains there is no evidence linking Zantac to an increased cancer risk and has not admitted liability.

GSK settles US Zantac lawsuit for $2.2bn

Shares of GSK are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits that claimed its discontinued heartburn drug Zantac caused cancer.

GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits

In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication.

Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday

British drugmaker agrees payment to resolve 80,000 cases alleging cancers were linked to drug known generically as ranitidine

GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.

GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits

GlaxoSmithKline (GSK, Financial) has agreed to a substantial settlement in connection with lawsuits related to its Zantac product in U.S. state courts. The company announced that it reached settlements with 10 plaintiff firms, which represent a significant 93% of the cases filed against the pharmaceutical company regarding Zantac.

GlaxoSmithKline Reaches $2.2 Billion Settlement in Zantac Lawsuits

GSK said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court Zantac product liability cases pending against the drugmaker, for up to $2.2 billion.

GSK reaches up to $2.2 billion settlement in Zantac US state court cases

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why GSK (GSK) is a Strong Value Stock

GSK (GSK, Financial) announced that its respiratory syncytial virus (RSV) vaccine has shown protective benefits for three quarters following vaccination. The cumulative efficacy of the vaccine, adjusted for seasonal factors, stands at 62.9% for the elderly.

GSK Reports Sustained Efficacy of RSV Vaccine Amidst Competition from Pfizer and Moderna

Recent data indicates a significant drop in the sales of the respiratory syncytial virus (RSV) vaccine in the United States. Major vaccine manufacturers, including GlaxoSmithKline (GSK, Financial), Moderna, and Pfizer, face decreasing demand as independent pharmacists report a two-thirds decline in RSV vaccine uptake compared to the previous year.

RSV Vaccine Demand Drops Sharply in the US, Impacting GSK's Sales

PHILADELPHIA--(BUSINESS WIRE)-- #AdultVaccination--GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons.

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

Pfizer

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.

GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the shot.

GSK RSV shot 43% effective against severe disease in third year

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine.

News for GlaxoSmithKline Stock (GSK)